BriaCell Continues Business and Clinical Operations During COVID-19 Pandemic
May 12 2020 - 5:30AM
BriaCell Therapeutics Corp. (“BriaCell” or the “Company”)
(TSX-V:BCT) (OTCQB:BCTXF), a clinical-stage biotechnology company
specializing in targeted immunotherapy for advanced breast cancer,
announces that the Phase I/IIa clinical study of Bria-IMT™, for
breast cancer treatment, with Incyte Corporation’s immune
checkpoint inhibitor, INCMGA00012, is ongoing and recruiting
patients amidst the COVID-19 pandemic. Further, BriaCell is
currently evaluating a number of business strategies to develop its
potential treatments for breast cancer on its own or in
partnership. BriaCell will be presenting the clinical and
pathological findings of Bria-IMT™, alone or in combination with
checkpoint inhibitors, KEYTRUDA® and INCMGA00012, in advanced
breast cancer will be presented at upcoming conferences including
2020 American Society of Clinical Oncology (ASCO) Meeting (May
29-Jun 2, 2020), and American Association for Cancer Research
(AACR) Annual Meeting in August 2020.
“We are
committed to develop treatment solutions for advanced breast cancer
patients with no effective treatment options and understand that
continuation of our clinical studies during these unprecedented
times is critical for our patients. We are grateful to our clinical
team for having made the task possible,” said Dr. Bill Williams,
BriaCell’s President & CEO.
About American Society of Clinical Oncology (ASCO)
Conference
Founded in 1964, ASCO is the world’s leading
professional organization for physicians, oncology professionals,
and research scientists in the field of oncology. ASCO’s Mission
over the years has been to conquering cancer through research,
education, and promotion of the highest quality patient care.
ASCO’s Annual meeting represents the world’s
largest gathering of oncology physicians, biotechnology executives,
researchers, patient advocates, and investment analysts to discuss
cutting-edge clinical research and therapeutics in oncology, and to
gain insights for improving cancer care.
About AACR
The AACR was founded in Washington, D.C., May 7,
1907, by a group of 11 physicians and scientists intending “to
further the investigation and spread the knowledge of cancer.” To
prevent and cure cancer using research, education, communication,
collaboration, funding and advocacy has been the mission of AACR.
With its programs and services, AACR advances research in cancer
and related biomedical science by facilitating exchange of
knowledge and innovations among scientists and clinicians dedicated
to the fight against cancer, providing education and training in
oncology treatment and advancing cancer etiology, prevention, early
detection, diagnosis and treatment worldwide.
About BriaCell
BriaCell is an immuno-oncology focused
biotechnology company developing targeted and effective approaches
for the management of cancer.
For additional information on BriaCell, please
visit: https://briacell.com/.
Cautionary Note Regarding Forward-Looking
Information
Except for the statements of historical fact,
this news release contains "forward-looking information" within the
meaning of the applicable Canadian securities legislation (also
known as "forward-looking statements") which are subject to known
and unknown risks relevant to the Company in particular and to the
biotechnology and pharmaceutical industries in general,
uncertainties and other factors that may cause actual events to
differ materially from current expectation. These risks are more
fully described in the Company's public filings available at
www.sedar.com.
These forward-looking statements include, but
are not limited to, BriaCell’s plans, objectives, expectations and
intentions. Such forward-looking statements reflect BriaCell's
current beliefs and are based on information currently available to
management. Although the forward-looking statements contained in
this news release are based upon what BriaCell believes are
reasonable assumptions, there can be no assurance that actual
results will be consistent with these forward-looking
statements.
Readers are cautioned not to place undue
reliance on these forward-looking statements, which speak only as
of the date of this press release. The Company disclaims any
intention or obligation, except to the extent required by law, to
update or revise any forward-looking statements, whether as a
result of new information, future events or otherwise.
Neither TSX Venture Exchange nor its Regulation
Services Provider (as that term is defined in the policies of the
TSX Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
Contact Information
For further information, please
contact:BriaCell Therapeutics Corp.:Farrah
DeanManager, Corporate DevelopmentEmail: farrah@BriaCell.comPhone:
1-888-485-6340
BriaCell Therapeutics (TSXV:BCT)
Historical Stock Chart
From Mar 2024 to Apr 2024
BriaCell Therapeutics (TSXV:BCT)
Historical Stock Chart
From Apr 2023 to Apr 2024